Biotransformation of lipids Figure 9. 4 Some examples of side chain degradation of 6B and 19 oxidosterols a: 3B-acetoxy-5a-bromo-6B, 19-0xidocholestane b: 5a-bromo-6B, 19-oXidoandrostane-3, 17-dione c∴:3β acetoxy-5α chloro6,19 oxidocholestane, 眠 19-oxidoandrost-4-ene-317-dione 19-oxido-4-cholestene-3-one f: 6B, 19-oxido-9a-hydroxyandrost-4-0ne-3, 17-dione .3.2 Use of enzyme inhibitors Earlier we icated that an alternative strategy to prevent ring cleavage is to use selective inhibition of the enzymes which catabolise the ring structure. The inhibitors used include: chelating agents metal ions with similar ion radii which will displace FeBiotransformation of lipids 303 Figure 9.4 Some examples of side chain degradation of Sp and 19 oxidosterols. a: 3p-acetoxy-5a-bromo-6p, 1 9-oxidocholestane, b: 5a-bromo-6p, 1 !3-oxidoandrostane-3,17dione, c: 3~acetoxy-5a-chloro-6p, 19 oxidocholestane, d: Sp, 19-oxMoandrost-4-ene-3,l irdione, e: Sp, 19-0xido-4-cholestene-3-0ne, f: Sp, 19-0xido-9a-hydroxyandrost-4-ene-3,17dione. 9.3.2 Use of enzyme inhibitors Earlier we indicated that an alternative strategy to prevent ring cleavage is tu use selective inhibition of the enzymes which catabolise the ring structure. The inhibitors used include: 0 chelating agents; 0 metal ions with similar ion radii which will displace Fez+;